Objective: To identify and measure recently described chemical mediators, termed specialized pro-resolving mediators that actively regulate the resolution of acute-inflammation, and correlate measurements with clinical outcomes. Design: Herein, deidentified plasma was collected from sepsis patients (n = 22 subjects) within 48 hours of admission to the ICU and on days 3 and 7 thereafter and subjected to lipid mediator profiling. Setting: Brigham and Women's Hospital Medical Intensive Care Unit. Subjects: Patients in the medical ICU with sepsis.
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Coordination of the immune response relies on host-and pathogen-derived classical signals (1) (2) (3) (5) (6) (7) . These include cytokines and chemokines (1, 5) and local chemical mediators, such as the potent leukocyte chemoattractant leukotriene B 4 , and prostaglandins that promote vascular leakage (6) . When the inflammatory response is self-contained, these mediators are protective.
In uncontrolled inflammation, their production may become dysregulated, a phenomenon linked with many conditions, including severe sepsis (3, (5) (6) (7) . It is now appreciated that endogenous chemical signals are produced that orchestrate the host response to promote resolution of local inflammation (2, 7). These novel leukocyte-derived mediators, coined specialized proresolving mediators (SPMs), are produced via enzymatic conversion of ω-3 essential fatty acids and include structurally distinct chemical families, such as the D-and E-series resolvins, protectins, and maresins (2) (Fig. 1) . Biosynthesized in the resolution phase, SPMs are agonists of resolution, as they actively counter regulate proinflammatory mediators (i.e., formation and actions of cytokines and lipid mediators [LMs]), promote phagocyte uptake and killing of bacteria (2, (7) (8) (9) (10) , enhance viral infection clearance (7, 11) , and control experimental endotoxemia (12) and bacterial infections (8, 10) . Resolvins and lipoxins are also organ protective, reducing leukocyte-mediated tissue damage (13) and fibrosis (14) . Of note, local and systemic SPM levels become dysregulated during experimental pneumonia in nonhuman primates (15) and are present in human serum, breast milk, and urine (16, 17) .
Recent immunophenotying studies demonstrate that in addition to the classical appreciation that hyperinflammation may lead to a negative outcome in several diseases, immune hypoactivation or suppression also leads to patient morbidity and death (18, 19) . In order to obtain further insights into mechanisms that lead to a failure of the host response to resolve during the infections, leading to sepsis and ultimately death in the present study, we investigated whether SPMs were present in the peripheral blood of human sepsis subjects. We then assessed their temporal regulation after ICU admission and whether levels of specific SPMs correlated with mortality. We further stratified the clinical data to determine whether SPMs might better predict clinical outcomes than traditional biomarkers and furthermore whether correlation of SPMs with clinical outcomes might point toward new underlying mechanisms for development of critical illness.
MATERIALS AND METHODS

Selection of Subjects for Analysis
This study was approved by the Partners Healthcare Institutional Review Board. Sepsis subjects with plasma samples collected within 48 hours of ICU admission (termed "day 1") and days 3 and 7 thereafter were obtained from the Brigham and Women's Hospital Registry of Critical Illness (20, 21) . Those surviving hospitalization ("survivors") and nonsurvivors were randomly selected from those with plasma samples of at least 1-mL volume (to allow sufficient material for the assays) available at the three time points. For additional details, please see supplementary material (Supplemental Digital Content 1, http://links.lww.com/CCM/C106).
LM Metabololipidomics and Statistical Analysis
Please see supplementary material (Supplemental Digital Content 1, http://links.lww.com/CCM/C106).
RESULTS
Subjects with sepsis were selected from our Registry of Critical Illness medical ICU (MICU) biorepository (20, 21) with the goal of examining LMs over 7 days in survivors and nonsurvivors (for additional details, see supplementary material, Supplemental Digital Content 1, http://links.lww.com/CCM/C106). Baseline demographic characteristics of subjects stratified by survival are summarized ( Table 1) . Nonsurvivors and survivors exhibited no significant differences, except that nonsurvivors had a higher acute physiology and chronic health evaluation (APACHE) II clinical score at admission. To rule out selection bias in selecting subjects for analysis, the 22 selected subjects were compared with a random sample of 30 nonselected patients (for additional details, see supplementary material, Supplemental Digital Content 1, http:// links.lww.com/CCM/C106) using 29 demographic variables and comorbidities. The occurrence of hematologic disorders was the only variable that differed significantly, with a higher occurrence among selected patients (45% vs 17%; p = 0.03).
To assess the presence of LMs in peripheral blood, we employed a targeted liquid chromatography-tandem mass spectrometry approach, permitting the identification and quantitation of more than 50 specific LMs and pathway markers of interest from the three major bioactive essential fatty . Although proresolving mediators were described initially as local mediators, they were demonstrable in sepsis plasma, raising the feasibility of these mediators as novel biomarkers. We next examined LM profiles from nonsurvivors versus survivors using partial least square discriminant analysis. We found that LM profiles for 21 of 22 patients clustered within ≈95% confidence region (white circle; LM profiles from six of nine nonsurvivors gave distinct clusters compared with survivors, and LMs in survivors produced a tighter cluster than in nonsurvivors. Assessment of loading plots from identified LMs demonstrated an association between proresolving mediators resolvin E2, LXB 4 , resolvin D2, and 15-epi-LXB 4 in survivors that gave variable importance in projection (VIP) scores more than 1. The major human lipoxygenase(s) each predominantly inserts oxygen in the S-configuration; R-stereochemistry (e.g., as that found in 15-epi-LXB4) can arise via either cytochrome P450 oxygenation (23) or from aspirin-triggered mechanisms (24) . There was also an association obtained for levels of inflammation-initiating eicosanoids prostaglandin E 2 and TxB 2 , the further inactive metabolite of the vasoactive TxA 2 (6) ( Fig. 2A) , in survivors.
LM profiles for survivors on day 3 gave greater separation compared with nonsurvivors ( Fig. 2B) with R 2 X = 0.4, R 2 Y = 0.7, and Q 2 = 0.5. Profiles from nonsurvivors on day 3 produced tighter clusters than on day 1. The loading plot demonstrated an association with VIP scores more than 1 for resolvin E1, 17-epi-protectin D1 (PD1), and 17-epi-resolvin D1 with nonsurvivors (Fig. 2B) . We also found an association of TxB 2 and prostaglandin D 2 with survivors with VIP scores for these products of ≈1. Profiles from day 7 also gave distinct clusters in survivors and nonsurvivors with R Fig. 2C) . We found an association of 17-epi-resolvin D3, resolvin E2, and resolvin D5 with nonsurvivors and LXB 4 and 15-epi-LXB 4 with survivors each giving a VIP score more than 1.
Day 1 proresolving mediators PD1 (0.7 ± 0.5 vs 0.0 ± 0.0 pg/mL; p < 0.05) and resolvin E1 (2.2 ± 0.9 vs 0.0 ± 0.0 pg/mL; p < 0.05) were significantly higher in nonsurvivors versus survivors. In nonsurvivors, we noted a significant increase in prostaglandin F 2α (Supplementary Table 1 , Supplemental Digital Content 4, http://links.lww.com/CCM/C109), a potent airway smooth muscle contractant. At day 3, we found significant increases in proresolving mediators resolvin D5 (4.9 ± 2.7 vs 0.2 ± 0.2 pg/mL; p < 0.05), resolvin E1 (1.7 ± 0.9 vs 0.3 ± 0.2 pg/ mL; p < 0.05), 17-epi-resolvin D1 (2.6 ± 1.0 vs 0.2 ± 0.1 pg/ mL; p < 0.05), and 17-epi-PD1 (1.8 ± 0.7 vs 0.3 ± 0.3 pg/mL; p < 0.05) and significant increases in prostaglandin F 2α (3.3 ± 1.2 vs 53.6 ± 29.0 pg/mL; p < 0.05) in nonsurvivors versus survivors (Supplementary Table 1 , Supplemental Digital Content 4, http:// links.lww.com/CCM/C109). Day 7 levels of resolvin D5 (6.8 ± 2.7 vs 0.4 ± 0.3 pg/mL; p < 0.05) and resolvin E2 (171.6 ± 58.9 vs 68.8 ± 21.0 pg/mL; p < 0.05) were significantly increased in sepsis nonsurvivors versus survivors (Supplementary Table 1 , Supplemental Digital Content 4, http://links.lww.com/CCM/ C109). Prostaglandin F 2α (51.3 ± 25.7 vs 4.7 ± 1.6 pg/mL; p < 0.05) levels were elevated in nonsurvivors versus survivors at day 7.
To determine whether SPMs correlate with mortality more reliably than clinical variables, we performed a comprehensive analysis of clinical variables and traditional cytokines. Selected variables stratified by survivors versus nonsurvivors (Tables 3  and 4 ) show significant increases in proinflammatory cytokines in nonsurvivors (tumor necrosis factor [TNF]-α at all three time points; interleukin [IL]-6 and IL-8 at day 7), significant reduction in platelet count in nonsurvivors (days 3 and 7), increased partial thromboplastin time in nonsurvivors (day 7), significant reduction in serum bicarbonate level in nonsurvivors (days 1 and 3), significant increase in intubation rates in nonsurvivors at days 3 and 7, and significantly lower Pao 2 and pH at day 1 in nonsurvivors. Additional variables measured include total bilirubin levels and pressor use (higher in nonsurvivors) and Glasgow Coma Scale scores (lower in nonsurvivors at three time points). Other variables not significantly different between survivors and nonsurvivors include full chemistries and liver function tests; use of therapeutic heparin, propofol, and total parenteral nutrition; use of vasopressors; and administration of antibiotics. We systematically compared the association between SPMs and mortality with the association between APACHE II and mortality (for details, see supplemental methods, Supplemental Digital Content 1, http://links.lww.com/CCM/C106). Although some SPMs were significantly correlated with mortality, with small sample size and low power, they did not predict survival more reliably than traditional clinical variables, so we next determined whether there was a subset of patients in whom SPM better predict clinical outcomes than traditional clinical variables.
The significant increase in the occurrence rate of mechanical ventilation and lower Pao 2 and pH values in nonsurvivors pointed toward increased respiratory failure in nonsurvivors, despite the fact that there was no significant difference in the number of subjects with ARDS between survivors and nonsurvivors ( Table 2) . Furthermore, causes of death in nonsurvivors largely reflected sequelae of respiratory failure. We therefore stratified subjects by ARDS presence as an indicator of antecedent respiratory failure (i.e., sepsis, n = 16 vs sepsis/ARDS, n = 6) ( Table 2 ) and examined LM ( Fig. 3; and Supplementary Table 2, Supplemental Digital Content 5, http://links.lww.com/CCM/ C110). LM profiles in ARDS patients demonstrated separation from sepsis patients on day 1 (Fig. 3A) . Analysis of loading plots demonstrated association (VIP score > 1) of prostaglandin F 2α with ARDS profiles, whereas 17-epi-resolvin D1 and resolvin D2 were associated with sepsis profiles (Fig. 3B) . Day 3 LM profiles gave better separation between the two clusters with R 2 X = 0.5, R 2 Y = 0.7, and Q 2 = 0.5 (Fig. 3C) . We also found strong correlation between sepsis patients and a select group of proresolving mediators, including 17-epi-resolvin D1 and resolvin D2 (Fig. 3D) . These characteristic LM profiles were also observed at day 7 from these two patient groups, giving distinct clusters (Fig. 3, E and F) . In contrast to the correlation of a number of clinical variables with nonsurvival (Tables 3 and 4 ), other than the higher incidence of respiratory failure in the sepsis/ARDS group (which is expected), there was no significant correlation of major clinical variables with the development of ARDS (Tables 5 and 6 ). We systematically compared the associations between SPMs and ARDS with the associations between APACHE II and ARDS development (for details, see supplemental methods, Supplemental Digital Content 1, http://links.lww.com/CCM/C106). Interestingly, we found that day 3 amount of 10S,17S-diHDHA (also known as "PDX") was significantly correlated with ARDS (p < 0.001) and was a significantly better predictor of ARDS development than APACHE II score (r = 0.79 vs 0.35; p < 0.01, one sided). Our results highlight the difficulty of predicting ARDS using clinical variables, even in atrisk subjects, making the significant differences in SPMs between sepsis and sepsis/ARDS groups that are much more striking.
DISCUSSION
We report identification of proresolving mediators in sepsis patients (Tables 1 and 2 ) and temporal relationships to classic proinflammatory and vasoactive eicosanoids. We found elevated plasma levels of LM-SPM in nonsurvivors and that peripheral blood LM profiles correlate with ARDS development in sepsis patients. These profiles were observed at ICU day 1 and persisted to day 7, suggesting that early measurements of LM-SPMs might serve as biomarkers, especially given that prostaglandin F 2α was found to be a strong predictor of mortality in sepsis patients (Supplementary Table 1 , Supplemental Digital Content 4, http://links.lww.com/CCM/C109). Interestingly, protectin D1 isomer 10S,17S-diHDHA correlated with ARDS development in sepsis patients, whereas traditional clinical variables were poor predictors of ARDS development (Tables 3-6 ). These peripheral blood LM profiles additionally indicate that in septic patients, the inflammatory response also includes the vascular system with an alteration of the peripheral blood LM profile, an increase in LM production, and a failure to engage proresolving mechanisms. We investigated circulating levels of known physiologic mediators involved in onset of inflammation and thrombosis (leukotrienes, prostaglandins, and thromboxanes) (6) and resolution of acute and chronic inflammation (SPM) (2, 7, 8, 10, 25) in sepsis patients with a variety of underlying conditions (Tables 1 and 2 ). Regulation of circulating levels of distinct clusters of mediators was different in survivors versus nonsurvivors with a signature present on day 1 that persisted to day 7 (Fig. 2) . At day 7, 10S,17S-diHDHA was a better predictor of ARDS development than the clinical APACHE II score, indicating that this protectin pathway marker represents a new early biomarker that may help stratify patients at MICU admission. In addition, nonsurvivors had higher circulating cytokines, lower platelet counts, and higher respiratory failure and ventilator dependence, further suggesting that SPMs correlate with outcomes in a subset of critically ill patients with respiratory failure (Supplementary Table 1 , Supplemental Digital Content 4, http://links.lww.com/CCM/C109).
Platelet activation is associated with sepsis severity and correlates with organ failure (26) . Resolvins regulate platelet activation and reduce adhesion molecule expression on platelets, leukocytes, and endothelial cells, thereby preventing homotypic and heterotypic aggregates and transcellular biosynthesis of inflammation-initiating mediators, including LTC 4 (23, 27, 28) . Aberrant platelet activation is also associated with cardiovascular complications. Aspirin, which acetylates cyclooxygenases, inhibiting prostaglandin and TxA 2 production, jumpstarts resolution via production of aspirin-triggered longer acting epimers of the lipoxins, resolvins, and protectins by acetylated cyclooxygenase-2 (2, 6, 24). Here we identified 17-epi-resolvin D1, 17-epi-resolvin D3, 17-epi-PD1, and 15-epi-LXB 4 in sepsis plasma that likely reflect aspirin acetylation of cyclooxygenase-2-or cytochrome P450-initiated mechanisms (23) . In sepsis nonsurvivors, we found significant increases in prostaglandin F 2α (Supplementary Table 1 regulate cyclooxygenase-2 expression (29), one of the enzymes responsible for prostaglandin F 2α biosynthesis, as well as the subcellular localization of 5-lipoxygenase, leading to a switch from leukotriene to lipoxin production (30) . Given potent biologic actions of SPM (2, 7, 8, 10, 23) , the present results suggest that the observed increases in the peripheral blood levels of these potent mediators in both sepsis nonsurvivors and ARDS patients may not be adequate to prevent and/or reverse the disease sequelae in these patients giving rise to as status of failed resolution. The failure of these proresolving mediators to regulate the inflammatory response may arise because of a failure of these molecules to interact with their cognate receptors potentially because of a down-regulation of these receptors as observed for other host protective receptors in sepsis, a hypothesis that will need to be investigated in future studies.
Despite decades of sepsis research, there are no targeted therapies that control the unbridled inflammatory response and organ failure (3, 4) . Many of the drugs tested, including anti-TNF-α agents and glucocorticoids, antagonize inflammatory responses by blocking upstream targets that catalyze dysregulated immune responses. However, inhibition of many of these proinflammatory pathways has not proven effective, likely due to the heterogeneity of molecular pathways activated in different patients and conditions. Importantly, anti-inflammatory treatments can also produce immune suppression that can be detrimental in host defense (3, 4) . Because the immune response is critical for clearance of microbial pathogens, new approaches are needed that spare the innate immune response.
Because there was increased incidence of respiratory failure in nonsurvivors (Tables 3 and 4) , we stratified SPMs by ARDS presence or absence (Fig. 3) and found that LM-SPM profiles from ARDS patients were distinct from sepsis at day 1 and persisted to day 7. Substratification of critically ill patients and prediction of ARDS development in at-risk patients are particularly challenging. Especially, given our small cohort and severity of illness, the correlation of SPMs with ARDS in the absence of clinical predictors of ARDS development (Tables 5  and 6 ) and the observation that the protectin pathway is better associated with ARDS development than APACHE II score further highlight the relevance of SPMs to critical illness and development of respiratory failure. PD1 was also significantly reduced in exhaled breath condensates from asthmatic patients (31) , indicating that the protectin pathway may be a component in lung homeostasis.
SPMs govern the inflammatory response without disrupting immune cell function in pre-clinical animal models and isolated phagocytes (2, 7, 8, 10) . SPM, including the D-series resolvins (resolvin D1, resolvin D2, and resolvin D5), protectins (PD1) and lipoxins (LXA 4 and LXB 4 ) are also produced in non-human primates (15) and mice (8) during bacterial infections at concentrations commensurate with their bioactive ranges; levels are decreased in non-resolving infections (8) . SPM promote clearance of bacteria, reduce local and systemic pro-inflammatory mediator production (8, 10, 11, 32) , and promote tissue repair and regeneration (2, 7) . SPM, such as the protectins, promote viral clearance via regulation of host responses (32), a property shared with resolvin E1 in Herpes simplex eye infections (33) , and by inhibiting viral replication (11) . Thus, our identification of SPM in peripheral blood at levels ≈ 1-500 pM is commensurate with their bioactive concentrations (0.1 pM to 10 nM), suggesting that they reflect physiologic role(s) in human sepsis. It is noteworthy that mediators up-regulated in sepsis nonsurvivors, including resolvin E1, resolvin D1, resolvin D5, and PD1 lower antibiotic requirements (8) , and protect against inflammationassociated cognitive decline (34) and age-associated inflammation (35, 36) in animal infections. In addition to a regulation of LMs in the nonsurvivors, we also found increased levels of inflammatory cytokines (Tables 3-6 ). These results suggest that in nonsurvivors, there is widespread systemic inflammation and a status of failed resolution, where although there is an increase in endogenous proresolving mediator production, their levels are not adequate to resolve the ongoing inflammation, ultimately resulting in death.
The primary objective of our study was to identify LM-SPM and validate their structures in peripheral blood of sepsis patients and secondarily to correlate levels with clinical outcomes. Using a patient cohort of 22 subjects who were randomly selected from those with available samples at all three time points, we observed striking profiles that distinctly separated sepsis survivors from nonsurvivors on day 1, with persistence to day 7, as well as sepsis patients who develop ARDS from those who do not. The selection of subjects with samples available for analysis at all three time points over a 7-day period suggests that the findings made in the present study may have been even more robust if we had made prospective measurements in all comers. Differences in comorbidities may also have an impact on the observed LM profiles (Supplementary Table 3 , Supplemental Digital Content 6, http://links.lww. com/CCM/C111). Indeed, we found significant associations between comorbidities and select LMs, including resolvin D1 with hematologic malignancies. Future studies will be important for prospective identification and monitoring of SPM in a larger cohort of sepsis and control subjects who will allow confirmation of their roles as potential biomarkers predictive of clinical outcomes. Such studies will allow analysis of sepsis subgroups, as SPM might have additional predictive value in subjects with the highest severity of illness. In addition, recent studies also demonstrate that soluble receptor for advanced glycation and end products (37, 38) and von Willebrand factor (38, 39) are predictive biomarkers of outcome in sepsis, and thus, it would be of future interest to determine the correlation of these biomarkers with SPM profiles in predicting outcomes in sepsis. In addition, a combination of these novel biomarkers may assist in providing better patient stratification.
We also identified the correlation between peripheral blood LM and outcomes in sepsis with significant increases in specific host protective mediators (resolvin E1, resolvin D5, 17-epiresolvin D1, 17-epi-PD1, and PD1) and a distinct signature at ICU admission. In nonsurvivors, we also found significant increases in a potent airway smooth muscle constrictor prostaglandin LM profiling can reflect patient status in critically ill subjects and sets the stage for LM-SPM signature profiling of pathway markers as a novel approach for evaluating outcomes and modulating treatment responses in sepsis.
